ALGOMEDIX

Algomedix is a small biotechnology company based in Mill Creek, Washington. The company employs five people and has generated $2.5 million in revenue. Algomedix focuses on developing targeted therapeutics for TRP (Transient Receptor Potential) channels, particularly TRPA1, which plays a role in pain, inflammation, ocular, and dermatological diseases. Their research has yielded novel small molecules that effectively target human TRPA1 with high potency and specificity, exhibiting desirable drug-like properties. These compounds represent a significant advancement in pain management, offering potential alternatives to opioids, NSAIDs, and gabapentanoids. Their primary mechanism of action targets pain at its source, minimizing adverse effects and reducing the risk of addiction or abuse. Algomedix's most advanced compound, protected by patents, is in late-stage preclinical development and poised to enter clinical trials. Algomedix's website is algomedix.com.